ALACT Stock Overview
Operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Acticor Biotech SAS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.34 |
| 52 Week High | €5.32 |
| 52 Week Low | €0.22 |
| Beta | -0.35 |
| 11 Month Change | -13.23% |
| 3 Month Change | -18.81% |
| 1 Year Change | -91.03% |
| 33 Year Change | -94.75% |
| 5 Year Change | n/a |
| Change since IPO | -95.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALACT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 3.3% | -7.7% | -0.3% |
| 1Y | -91.0% | -26.4% | -3.5% |
Return vs Industry: ALACT underperformed the French Biotechs industry which returned -26.5% over the past year.
Return vs Market: ALACT underperformed the French Market which returned -2.5% over the past year.
Price Volatility
| ALACT volatility | |
|---|---|
| ALACT Average Weekly Movement | 33.9% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALACT's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALACT's weekly volatility (34%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 31 | Gilles Avenard | www.acticor-biotech.com |
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It’s product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19).
Acticor Biotech SAS Fundamentals Summary
| ALACT fundamental statistics | |
|---|---|
| Market cap | €5.48m |
| Earnings (TTM) | -€16.47m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs ALACT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALACT income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €16.47m |
| Earnings | -€16.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -137.0% |
How did ALACT perform over the long term?
See historical performance and comparison